Previously recorded as MedImmune Vaccines, Inc. (to 2008)
213 patents currently held
60 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Of the 60 now held by other companies, 9 name Humabs Biomed S.A. as their current owner, and 51 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
21
Ending by 2030
Jan 2027
Next term end
128
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2030 · High confidence
Also notable
Ends Jun 2035 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Jun 2036 · High confidence
Also notable
Ends Jan 2027 · High confidence
Also notable
Ends Oct 2029 · Medium confidence
Also notable
Ends Feb 2034 · High confidence
Also notable
Ends no later than May 2035 · Medium confidence
Targeted Binding Agents Against B7-H1
US 8,779,108
The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.
Methods of Treatment with Antagonists Against PD-1 and PD-L1 in Combination with Radiation Therapy
US 10,092,645
Cited by 20 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Binding Molecules Specific for CD73 and Uses Thereof
US 9,938,356
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Neutralizing Anti-Influenza Binding Molecules and Uses Thereof
US 10,442,854
Cited by 26 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2036.
Non-Tumorigenic MDCK Cell Line for Propagating Viruses
US 7,670,837
Cited by 84 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Unsymmetrical Pyrrolobenzodiazepine-Dimers for Treatment of Proliferative Diseases
US 8,940,733
Cited by 70 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Combination Therapies Using Anti-Pseudomonas PSL and PCRV Binding Molecules
US 10,597,439
Cited by 11 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2034.
ANTI-B7-H1 and ANTI-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
US 10,232,040
Cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Jan 2 to 18, 2027 · next Jan 2
- 2 fees due Feb 6 to 28, 2027 · next Feb 6
- 4 fees due Mar 1 to 26, 2027 · next Mar 1
- 8 fees due Apr 3 to 29, 2027 · next Apr 3
- 5 fees due May 3 to 28, 2027 · next May 3
- 5 fees due Jun 15 to 30, 2027 · next Jun 15
- 2 fees due Jul 14 to 28, 2027 · next Jul 14
- 6 fees due Aug 9 to 27, 2027 · next Aug 9
- 5 fees due Sep 3 to 26, 2027 · next Sep 3
- 2 fees due Oct 30, 2027
- 2 fees due Nov 12 to 19, 2027 · next Nov 12
Recent changes
- Nov 9Assignment recorded on 1 record: AstraZeneca UK Limited to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 866.
- Nov 9Assignment recorded on 1 record: Reid, Fred and 2 others to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 869.
- 7 of the patents on this record were granted since Aug 23, 2026
- 7 terms have ended since Aug 23, 2026
- Nov 13 US 8,697,396 Modulation Of Antibody Effector Function By Hinge Domain Engineering · term ended
- Oct 13 US 9,567,389 Cell Display Of Antibody Libraries · term ended
- Oct 13 US 8,409,568 Mutant Antibody FC Domains and Fusion Proteins Thereof · term ended
- Oct 7 US 8,852,608 Antibodies Against and Methods for Producing Vaccines for Respiratory Syncytial Virus · lapsed on the fee record
- Sep 11 US 10,072,083 Method for Purifying Active Polypeptides or Immunoconjugates · lapsed on the fee record
- Sep 9 US 9,096,658 Antibodies Against and Methods for Producing Vaccines for Respiratory Syncytial Virus · term ended
- Aug 30 US 11,426,467 Dosage Regimes for the Administration of an ANTI-CD25 Adc · lapsed on the fee record
What they patent
The largest of its 128 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,670,837 | Non-Tumorigenic MDCK Cell Line for Propagating Viruses In force · High confidence | In force | High confidence | |
| US 8,846,032 | MDCK Cell Lines Supporting Viral Growth to High Titers and Bioreactor Process Using the Same In force · High confidence | In force | High confidence | |
| US 9,005,620 | Compounds In force · Medium confidence | In force | Medium confidence | |
| US 8,008,443 | Modulation of Antibody Effector Function by Hinge Domain Engineering In force · High confidence | In force | High confidence | |
| US 8,666,778 | Systems and Methods for Processing Requests for Pharmaceuticals That Require Insurer Preapproval In force · Medium confidence | In force | Medium confidence | |
| US 7,790,655 | Cell Display of Antibody Libraries In force · High confidence | In force | High confidence | |
| US 7,790,434 | Methods and Compositions for Expressing Negative-Sense Viral RNA in Canine Cells In force · High confidence | In force | High confidence | |
| US 9,176,129 | Protein Scaffolds In force · High confidence | In force | High confidence | |
| US 8,137,670 | Method of Identifying Membrane Ige Specific Antibodies and Use Thereof for Targeting Ige Producing Precursor Cells In force · High confidence | In force | High confidence | |
| US 9,193,789 | Anti-Icos Antibodies and Their Use in Treatment of Oncology, Transplantation and Autoimmune Disease In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 213: 60 patents in force now held by others · 218 patents ended · 145 applications pending · 371 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.